RT Journal Article
SR Electronic
T1 The spread of a validated molecular marker of artemisinin partial resistance <em>pfkelch13</em> R622I and association with <em>pfhrp2/3</em> deletions in Eritrea
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.20.23297302
DO 10.1101/2023.10.20.23297302
A1 Mihreteab, Selam
A1 Anderson, Karen
A1 Molina - de la Fuente, Irene
A1 Sutherland, Colin J.
A1 Smith, David
A1 Cunningham, Jane
A1 Beshir, Khalid B
A1 Cheng, Qin
YR 2023
UL http://medrxiv.org/content/early/2023/10/21/2023.10.20.23297302.abstract
AB Eritrea is the first African country to switch away from exclusive use of HRP2-based RDTs for the detection of P. falciparum due to high prevalence of pfhrp2/3-deleted P. falciparum parasites causing false-negative RDT results. While heavy reliance on malaria RDTs played a significant role in the rapid expansion of pfhrp2/3-deleted parasites in Eritrea, we hypothesize that the use of antimalarial (artesunate-amodiaquine) may have also contributed to their spread. We conducted a retrospective investigation of mutations in the propeller domain of the P. falciparum kelch13 gene in samples collected in 2016 (n=50) from the Northern Red Sea Zone before the RDT switch away from HRP2-RDTs and in samples collected in 2018-2020 (n=587) from the Gash Barka, Anseba and Debub Zones after the RDT switch. No mutations were identified in the 2016 samples. However, in 2018-2019 samples, we detected five different single non-synonymous mutations. The most prevalent mutation was pfk13 R622I, which was detected in samples collected from all health centres, with an overall prevalence of 11.9% (ranging from 5.9% to 28%). Parasites carrying the R622I mutation have diverse microsatellite marker haplotypes, indicating that they had evolved multiple times from different genetic backgrounds. The prevalence pfk13 R622I was significantly higher in single pfhrp3-deleted parasites (18.0%) compared to parasites without pfhrp2/3 deletions (6.2%) and dual pfhrp2/3-deleted parasites (9.0%), suggesting association between the pfk13 R622I mutation and the pfhrp2/3 deletions in Eritrea. Continuous monitoring the trends in pfhrp2/3 and pfk13 mutants is needed to inform effective malaria management strategies in Eritrea.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis laboratory work was supported by the US DoD Armed Forces Health Surveillance Division, Global Emerging Infections Surveillance Branch (AFHSD/GEIS), PROMIS ID P0111_22_AF and Wellcome Trust Institutional Strategic Support Fund to KBB (204928/Z/16/Z) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The surveys of pfhrp2/3 deletions were granted approval by the Eritrean MOH Research and Ethical Committee. Laboratory analyses on collected samples received approval from the Departments of Defence and Veterans Affairs Human Research Ethics Committee (DDVA HREC 15-004). Additionally, the severe malaria study was granted approval by LSHTM Ethics Review Committee (#11979).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors